Assessment of patent foramen ovale closure in elderly patients with cryptogenic transient ischemic attack or stroke: Efficacy, safety, and potential age-related benefit
European Stroke Journal · 2025
DOI: 10.1177/23969873251341764 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Stroke Journal, 2025. Verfasst von Chi-Sheng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Foramen Ovale, Patent, Ischemic Attack, Transient, Ischemic Stroke, Stroke. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
The efficacy and safety of patent foramen ovale closure (PFOC) in cryptogenic stroke (CS) patients aged ⩾ 60 remain controversial. This study evaluates the efficacy and safety of PFOC in elderly (aged ⩾ 60) versus non-elderly (aged < 60) patients and examines potential age-related benefit. Patients and methods: A hospital-based cohort study (January 2013–June 2023) compared the efficacy and safety between PFOC and non-PFOC groups in patient with CS or cryptogenic TIA. The primary efficacy outcome was recurrent ischemic stroke, and safety outcomes included procedure-related adverse events and periprocedural atrial fibrillation (AF). Subgroup analyses, including various age ranges, were performed for the elderly group.
Results
Among 239 patients (mean age 57.2 years), 120 were elderly. During a mean follow-up of 3.1 years, the PFOC group had significantly fewer recurrent ischemic stroke than the non-PFOC group (adjusted hazard ratio (AHR): 0.10, 95% CI: 0.03–0.29, p = 0.001). The risk reduction was similar in elderly (AHR: 0.11, p = 0.004) and non-elderly (AHR: 0.10, p = 0.005) patients (p for interaction = 0.337). Safety outcomes were comparable across age groups, including younger elderly (60–70) and older elderly (⩾70). No life-threatening complications occurred; one patient required additional intervention. Subgroup analysis indicated significant risk reduction for patients aged ⩾ 65 (AHR: 0.01, p = 0.012) but not for those aged 60–65 (AHR: 0.24, p = 0.071). Discussion and conclusion: PFO closure is safe and effective in elderly patients with CS. Advanced age should not be a contraindication for PFOC, as older patients may potentially derive more significant benefits from the procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurology, Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Pediatrics and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Pediatric Cardiology, Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.
- Center for Quality Management, Taichung Veterans General Hospital, Taichung, Taiwan.
- College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Chi-Sheng Wang, Po-Lin Chen
Zitieren
APA
Wang, C. S., Wu, Y. H., Fu, Y. C., Jan, S. L., Lin, M. C., Hsu, C. Y., & Chen, P. L. (2025). Assessment of patent foramen ovale closure in elderly patients with cryptogenic transient ischemic attack or stroke: Efficacy, safety, and potential age-related benefit. European Stroke Journal. https://doi.org/10.1177/23969873251341764
Vancouver
Wang CS, Wu YH, Fu YC, Jan SL, Lin MC, Hsu CY, et al. Assessment of patent foramen ovale closure in elderly patients with cryptogenic transient ischemic attack or stroke: Efficacy, safety, and potential age-related benefit. European Stroke Journal. 2025. doi:10.1177/23969873251341764
BibTeX
@article{Wang2025,
author = {Wang, Chi-Sheng and Wu, Yu-Hsuan and Fu, Yun-Ching and Jan, Sheng-Ling and Lin, Ming-Chih and Hsu, Chiann-Yi and Chen, Po-Lin},
title = {Assessment of patent foramen ovale closure in elderly patients with cryptogenic transient ischemic attack or stroke: Efficacy, safety, and potential age-related benefit},
journal = {European Stroke Journal},
year = {2025},
doi = {10.1177/23969873251341764}
}
EUVIMED